Graypoint LLC Has $1.66 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Graypoint LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 5,164 shares of the medical research company’s stock after acquiring an additional 148 shares during the period. Graypoint LLC’s holdings in Amgen were worth $1,664,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of AMGN. Strategic Financial Concepts LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $26,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $30,000. nVerses Capital LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $33,000. Finally, Matrix Trust Co acquired a new position in shares of Amgen in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Sanford C. Bernstein assumed coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective on the stock. TD Cowen boosted their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Finally, StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $333.50.

Amgen Stock Up 0.0 %

Shares of AMGN opened at $321.91 on Friday. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The firm has a market cap of $173.04 billion, a P/E ratio of 41.22, a price-to-earnings-growth ratio of 2.79 and a beta of 0.60. The firm’s 50-day simple moving average is $323.96 and its 200 day simple moving average is $316.68. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the prior year, the business earned $4.96 EPS. Amgen’s quarterly revenue was up 23.2% on a year-over-year basis. On average, analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 2.80%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.